Altogether, these pathological mechanisms lead to abnormal BDNF/TrkB-signaling which contributes to excitotoxicity, pointing to TrkB-FL and TrkB-T1 as relevant therapeutic targets for treatment of stroke and excitotoxicity-associated pathologies. Here, NTRK2 is linked to Stroke.